BRAF and non-small cell lung carcinoma: Given these results, in 2016, the Food and Drug Administration (FDA) approved this drug for treatment of advanced NSCLC in patients harboring BRAFV600E mutation [15], and a molecular-level targeted approach was adopted for BRAF-mutant NSCLCs.